Characterization of Osteolytic, Osteoblastic, and Mixed Lesions in a Prostate Cancer Mouse Model Using 18F-FDG and 18F-fluoride PET/CT

Overview

Journal J Nucl Med

Specialty Nuclear Medicine

Date 2008 Feb 22

PMID 18287261

Citations 36

Authors

Wellington K Hsu

Mandeep S Virk

Brian T Feeley

David B Stout

Arion F Chatziioannou

Jay R Lieberman

Affiliations

Soon will be listed here.

Abstract

Unlabelled: The combination of small-animal PET/CT scans and conventional imaging methods may enhance the evaluation of in vivo biologic interactions of murine models in the study of prostate cancer metastasis to bone.

Methods: Small-animal PET/CT scans using (18)F-fluoride ion and (18)F-FDG coregistered with high-resolution small-animal CT scans were used to longitudinally assess the formation of osteoblastic, osteolytic, and mixed lesions formed by human prostate cancer cell lines in a severe combined immunodeficient (SCID) mouse tibial injection model. These scans were correlated with plain radiographs, histomorphometry, and soft-tissue measurements.

Results: Small-animal PET/CT scans were able to detect biologic activity of cells that induced an osteoblastic lesion 2 wk earlier than on plain radiographs. Furthermore, both the size and the activity of the lesions detected on PET/CT images significantly increased at each successive time point (P < 0.05). (18)F-FDG lesions strongly correlated with soft-tissue measurements, whereas (18)F-fluoride ion activity correlated with bone volume measured on histomorphometric analysis (P < 0.005). Osteolytic lesions were successfully quantified using small-animal CT, whereas lesion sizes measured on (18)F-FDG PET scans also strongly correlated with soft-tissue tumor burden (P < 0.05). In contrast, for mixed lesions, (18)F-fluoride ion and (18)F-FDG PET/CT scans detected only minimal activity.

Conclusion: (18)F-FDG and (18)F-fluoride ion PET/CT scans can be useful tools in characterizing pure osteolytic and osteoblastic lesions induced by human prostate cancer cell lines. The value of this technology needs further evaluation to determine whether these studies can be used effectively to detect more subtle responses to different treatment regimens in animal models.

Citing Articles

Glycolytic potential enhanced by blockade of pyruvate influx into mitochondria sensitizes prostate cancer to detection and radiotherapy.

Xu H, Chen J, Cao Z, Chen X, Huang C, Ji J Cancer Biol Med. 2022; 19(9).

PMID: 35972052 PMC: 9500223. DOI: 10.20892/j.issn.2095-3941.2021.0638.

Association of Regional Bone Synthetic Activities of Vertebral Corners and Vertebral Bodies Quantified Using F-Fluoride Positron Emission Tomography with Bone Mineral Density on Dual Energy X-ray Absorptiometry in Patients with Ankylosing Spondylitis.

Kim K, Pak K, Kim I, Kim S, Sohn D, Kim A J Clin Med. 2020; 9(8).

PMID: 32824431 PMC: 7465964. DOI: 10.3390/jcm9082656.

A NF-ĸB-Activin A signaling axis enhances prostate cancer metastasis.

Chen L, De Menna M, Groenewoud A, Thalmann G, Kruithof-de Julio M, Snaar-Jagalska B Oncogene. 2019; 39(8):1634-1651.

PMID: 31740783 DOI: 10.1038/s41388-019-1103-0.

Deletion of Orai1 leads to bone loss aggravated with aging and impairs function of osteoblast lineage cells.

Choi H, Srikanth S, Atti E, Pirih F, Nervina J, Gwack Y Bone Rep. 2018; 8:147-155.

PMID: 29955633 PMC: 6020256. DOI: 10.1016/j.bonr.2018.03.007.

Utility of F-18 FDG PET/CT for Detection of Bone Marrow Metastases in Prostate Cancer Patients Treated with Radium-223.

Maruyama K, Utsunomia K, Nakamoto T, Kawakita S, Murota T, Tanigawa N Asia Ocean J Nucl Med Biol. 2018; 6(1):61-67.

PMID: 29333469 PMC: 5765335. DOI: 10.22038/aojnmb.2017.9896.

References

Flower M, Zweit J, Hall A, Burke D, Davies M, Dworkin M . 62Cu-PTSM and PET used for the assessment of angiotensin II-induced blood flow changes in patients with colorectal liver metastases. Eur J Nucl Med. 2001; 28(1):99-103. DOI: 10.1007/s002590000410. View

Plonowski A, Schally A, Varga J, Rekasi Z, Hebert F, Halmos G . Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways. Prostate. 2000; 44(2):172-80. DOI: 10.1002/1097-0045(20000701)44:2<172::aid-pros10>3.0.co;2-z. View

Morris M, Akhurst T, Larson S, Ditullio M, Chu E, Siedlecki K . Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy. Clin Cancer Res. 2005; 11(9):3210-6. PMC: 2040333. DOI: 10.1158/1078-0432.CCR-04-2034. View

Oyama N, Akino H, Suzuki Y, Kanamaru H, Miwa Y, Tsuka H . Prognostic value of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography imaging for patients with prostate cancer. Mol Imaging Biol. 2003; 4(1):99-104. DOI: 10.1016/s1095-0397(01)00065-6. View

Bylund A, Zhang J, Bergh A, Damber J, Widmark A, Johansson A . Rye bran and soy protein delay growth and increase apoptosis of human LNCaP prostate adenocarcinoma in nude mice. Prostate. 2000; 42(4):304-14. DOI: 10.1002/(sici)1097-0045(20000301)42:4<304::aid-pros8>3.0.co;2-z. View

Koutsilieris M, Rabbani S, Bennett H, Goltzman D . Characteristics of prostate-derived growth factors for cells of the osteoblast phenotype. J Clin Invest. 1987; 80(4):941-6. PMC: 442330. DOI: 10.1172/JCI113186. View

Kasper S, Smith Jr J . Genetically modified mice and their use in developing therapeutic strategies for prostate cancer. J Urol. 2004; 172(1):12-9. DOI: 10.1097/01.ju.0000132122.93436.aa. View

Herschman H . Micro-PET imaging and small animal models of disease. Curr Opin Immunol. 2003; 15(4):378-84. DOI: 10.1016/s0952-7915(03)00066-9. View

Chow P, Stout D, Komisopoulou E, Chatziioannou A . A method of image registration for small animal, multi-modality imaging. Phys Med Biol. 2006; 51(2):379-90. PMC: 3005360. DOI: 10.1088/0031-9155/51/2/013. View

10.

Hamacher K, Coenen H, Stocklin G . Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med. 1986; 27(2):235-8. View

11.

Whang P, Schwarz E, Gamradt S, Dougall W, Lieberman J . The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone. J Orthop Res. 2005; 23(6):1475-83. DOI: 10.1016/j.orthres.2005.05.004.1100230634. View

12.

Chatziioannou A, Cherry S, Shao Y, Silverman R, Meadors K, Farquhar T . Performance evaluation of microPET: a high-resolution lutetium oxyorthosilicate PET scanner for animal imaging. J Nucl Med. 1999; 40(7):1164-75. PMC: 3272501. View

13.

Blau M, Nagler W, Bender M . Fluorine-18: a new isotope for bone scanning. J Nucl Med. 1962; 3:332-4. View

14.

Gamradt S, Feeley B, Liu N, Roostaeian J, Lin Y, Zhu L . The effect of cyclooxygenase-2 (COX-2) inhibition on human prostate cancer induced osteoblastic and osteolytic lesions in bone. Anticancer Res. 2005; 25(1A):107-15. View

15.

Machtens S, Boerner A, Hofmann M, Knapp W, Jonas U . [Positron emission tomography (PET) for diagnosis and monitoring of treatment for urological tumors]. Urologe A. 2004; 43(11):1397-409. DOI: 10.1007/s00120-004-0714-3. View

16.

Landis S, Murray T, Bolden S, Wingo P . Cancer statistics, 1999. CA Cancer J Clin. 1999; 49(1):8-31, 1. DOI: 10.3322/canjclin.49.1.8. View

17.

Shreve P, Grossman H, Gross M, Wahl R . Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. Radiology. 1996; 199(3):751-6. DOI: 10.1148/radiology.199.3.8638000. View

18.

Edinger M, Sweeney T, Tucker A, Olomu A, Negrin R, Contag C . Noninvasive assessment of tumor cell proliferation in animal models. Neoplasia. 2000; 1(4):303-10. PMC: 1508101. DOI: 10.1038/sj.neo.7900048. View

19.

Gambhir S, Herschman H, Cherry S, Barrio J, Satyamurthy N, Toyokuni T . Imaging transgene expression with radionuclide imaging technologies. Neoplasia. 2000; 2(1-2):118-38. PMC: 1550287. DOI: 10.1038/sj.neo.7900083. View

20.

Piert M, Zittel T, Becker G, Jahn M, Stahlschmidt A, Maier G . Assessment of porcine bone metabolism by dynamic. J Nucl Med. 2001; 42(7):1091-100. View